Hypersomnia Pipeline Analysis Report 2026

Report Coverage

The Hypersomnia Pipeline Analysis Report by Expert Market Research gives comprehensive insights into hypersomnia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hypersomnia. The hypersomnia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hypersomnia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hypersomnia treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hypersomnia.

Read more about this report - Request a Free Sample

Hypersomnia Pipeline Outlook

Hypersomnia is a neurological sleep disorder characterized by excessive daytime sleepiness despite sufficient or extended nighttime rest. It occurs due to dysfunction in the brain regions regulating the sleep–wake cycle, often linked to genetic, neurological, or idiopathic factors. Individuals may struggle to wake up, experience confusion after sleep, and feel unrefreshed after naps.

Hypersomnia treatment focuses on symptom management through behavioral therapies, stimulant medications, and lifestyle adjustments to improve wakefulness, sleep quality, and cognitive functioning. In August 2021, Jazz Pharmaceuticals received FDA approval for Xywav (JZP258) as the first treatment for idiopathic hypersomnia in adults. This lower sodium oxybate therapy demonstrated strong efficacy and safety in Phase 3 trials.

Hypersomnia Epidemiology

According to University Hospitals data, 2025, hypersomnia disorders such as narcolepsy and idiopathic hypersomnia show varied global prevalence. Narcolepsy affects between 25 and 50 per 100,000 individuals, while idiopathic hypersomnia ranges from 2 to 10.3 per 100,000. As per Yu-Shu Huang et al., 2025, the prevalence of narcolepsy varies significantly across regions, with rates as high as 590 per 100,000 in Japan and as low as 0.23 per 100,000 in Israel. In the United States, estimates range between 37.7 and 79.4 per 100,000, while Asian studies report 15 to 37.5 per 100,000. These findings highlight substantial regional variation, emphasizing the need for improved diagnosis and consistent epidemiological research.

Hypersomnia – Pipeline Therapeutic Assessment

Hypersomnia Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total hypersomnia clinical trials, at 56%. It is followed by phase III at 28% and phase IV at 11%. The strong presence of late-stage trials underscores significant clinical progress, expected to drive therapeutic innovation and growth in the hypersomnia drug market.

Hypersomnia Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the hypersomnia pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The hypersomnia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hypersomnia. Sodium oxybate-based therapies are gaining prominence in the hypersomnia drug pipeline due to their effectiveness in managing excessive daytime sleepiness and sleep inertia. In June 2025, Avadel Pharmaceuticals announced that Lumryz, its extended-release sodium oxybate formulation, received orphan drug designation from the FDA for idiopathic hypersomnia. The once per night dosing of Lumryz improves treatment adherence and patient convenience compared to traditional twice-nightly regimens.

Hypersomnia Clinical Trials – Key Players

The EMR report for the hypersomnia pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hypersomnia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hypersomnia clinical trials:

• Avadel
• Alkermes, Inc.
• Takeda
• Centessa Pharmaceuticals (UK) Limited
• Harmony Biosciences Management, Inc.
• Axsome Therapeutics, Inc.
• Masimo Corporation
• Millennium Pharmaceuticals, Inc.
• Jazz Pharmaceuticals
• Zevra Therapeutics

Hypersomnia – Emerging Drugs Profile

Key Questions Answered in the Hypersomnia Pipeline Insight Report

• Which companies/institutions are leading the hypersomnia drug development?
• What is the efficacy and safety profile of the hypersomnia pipeline drugs?
• Which company is leading the hypersomnia pipeline development activities?
• What is the current hypersomnia commercial assessment?
• What are the opportunities and challenges present in the hypersomnia pipeline landscape?
• Which company is conducting major trials for hypersomnia drugs?
• Which companies/institutions are involved in hypersomnia collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Hypersomnia?

Reasons To Buy This Report

The Hypersomnia Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for hypersomnia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hypersomnia collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Hypersomnia Epidemiology Forecast

Narcolepsy Drugs Market

Narcolepsy Pipeline Analysis Report